Silence Therapeutics (SLN) Operating Income (2024 - 2026)

Silence Therapeutics has disclosed Operating Income across 3 years of filings, most recently posting -$15.7 million for Q1 2026.

• Operating Income for Q1 2026 came in at -$15.7 million, up 44.61% year-over-year; the trailing twelve-month figure through Mar 2026 was -$9.5 million (up 89.0% YoY), and the FY2025 annual result was -$22.2 million, up 65.02% from the prior year.
• Operating Income came in at -$15.7 million for Q1 2026 at Silence Therapeutics, down from $56.5 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $56.5 million in Q4 2025 to a low of -$30.0 million in Q3 2024.
• The 3-year median for Operating Income is -$23.4 million (2024), against an average of -$11.2 million.
• Peak annual rise in Operating Income reached 1397.47% in 2025, while the deepest fall reached 409.03% in 2025.
• Silence Therapeutics' Operating Income stood at -$4.4 million in 2024, then soared by 1397.47% to $56.5 million in 2025, then sank by 127.87% to -$15.7 million in 2026.
• The last three Operating Income figures came in at -$15.7 million (Q1 2026), $56.5 million (Q4 2025), and -$26.2 million (Q3 2025), per Business Quant data.